Navigation Links
Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Date:12/18/2007

Essential Tremor. In 2002, the European Journal of Neurology reported that there is a 20- to 30-percent misdiagnosis rate in the early stages of Parkinson's disease. Other publications have reported even higher rates of misdiagnosis. We believe that the accurate differentiation of Parkinsonian from non-Parkinsonian tremors could have important clinical implications. Physicians may be able to initiate earlier referral for specialty care, prescribe effective treatments, and provide a more-informed prognosis for patients and their families. If these trials are successful and the drug is approved, we believe that ALTROPANE could be a highly-selective central nervous system diagnostic molecular imaging agent -- and a valuable tool to help clinicians make better, more-accurate diagnoses.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world- class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 As of ... of incontinence devices for women. "Shipping ... most gratifying part is the hundreds of letters, ... whose lives have been positively impacted by our ... InControl. InControl recently released Apex, an ...
(Date:3/27/2015)... --  Hospira, Inc. (NYSE: HSP ), ... leading provider of injectable drugs and infusion technologies, ... biosimilarity of its proposed biosimilar, Epoetin Hospira, with ... approved name of RETACRIT™, compared to the reference ... were presented at the National Kidney Foundation (NKF) ...
(Date:3/27/2015)... -- Johnson & Johnson (NYSE: JNJ ) will webcast its ... Thursday, April 23, 2015, from the State Theatre in ... other interested parties may access the live audio webcast of ... and clicking on the webcast icon. A ... a few hours after the live meeting concludes.  The webcast ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... LOUIS, March 1, 2011 K-V Pharmaceutical Company (NYSE: KVa/KVb) ... million of senior secured notes due 2015 (the "Notes") in ... The Notes will be offered only to accredited investors pursuant ... amended (the "Securities Act").  The Notes have not been registered ...
... Medical Systems Ltd. (Nasdaq: DHRM ) ... the development, assembly, marketing and sale of medical ... announced that management will present at the following ... http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) Rodman & Renshaw ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 2K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 3K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 4K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 5K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 6K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 7K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 8Dehaier Medical Announces March Investor Presentations 2
(Date:3/28/2015)... (PRWEB) March 28, 2015 Early surgery ... with Type V AC joint injuries, according to new ... today at the American Orthopaedic Society for Sports Medicine’s ... to duty faster when surgery was not performed. , ... 7 receiving surgical treatment and 17 receiving non-surgical therapy. ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s ... the Chesapeake Conference Center in Chesapeake, Virginia. Each year, ... for women in the Hampton Roads region. The 2015 ... Lives. Women grow stronger through sharing their stories and ... year the WWC™ theme is T-talk where we will share ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... from dating experts Samantha Sanderson and Jason Rogers has ... buzz of media attention. The commotion surrounding the course's ... prompting him to publish an in-depth review of the ... when the men in their lives suddenly start pulling ...
(Date:3/27/2015)... York, New York (PRWEB) March 27, 2015 ... ( http://www.lipitorlawsuitcenter.com/ ) that allege the statin medication increases ... diabetes has granted Pfizer Inc.’s Motion to Dismiss four ... According to a Case Management Order issued in the ... 23rd, the Court determined that the dismissals were warranted ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... increased 48% over 2006 to $701 million, SAN ... ) today reported financial results for the quarter and,year ... of $222.0,million for the quarter ended December 31, 2007, ... was $76.9 million, or $0.57 per share for,the quarter ...
... Launch Vitals.com Which Offers Free Comprehensive Doctor ... Information and Reviews, ... one of the,nation,s top 10 public relations firms, today announced the ... execute a,comprehensive communications program for the free, online doctor evaluation,service., ...
... with chronic hepatitis C (HCV) infection should not ... published in Clinical Gastroenterology and Hepatology , ... (AGA) Institute. Researchers found that HCV patients who ... of moderate to severe liver fibrosis, or tissue ...
... need of support, THOUSAND OAKS, Calif., Jan. ... experience for women with only a fading,reference to ... Mental,Health Association, in the first three months after ... or exhibit negative,behavior toward their infant. Mothers experiencing ...
... The more scientists learn about microRNAs short strands ... the more obvious it becomes how closely they ... at The Wistar Institute and their colleagues have identified ... metastasis. One of the miRNAs may provide an early ...
... Psychological interventions for cancer patients do more than just ... research suggests. , A study of 227 breast cancer ... intervention program were rated as having better health by ... started. , One particularly important result was that patients ...
Cached Medicine News:Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 2Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 3Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 4Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 5Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 6Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 7Health News:MWW Group Selected by First-Ever Online Doctor Evaluation Service Vitals.com 2Health News:Regular marijuana use increases risk of hepatitis C-related liver damage 2Health News:Regular marijuana use increases risk of hepatitis C-related liver damage 3Health News:Blue Cross of California Launches Maternity Depression Program 2Health News:Blue Cross of California Launches Maternity Depression Program 3Health News:2 microRNAs promote spread of tumor cells 2Health News:2 microRNAs promote spread of tumor cells 3Health News:Intervention program boosts health, reduces symptoms in breast cancer patients 2Health News:Intervention program boosts health, reduces symptoms in breast cancer patients 3
... Kendall provides hospitals and alternate care ... tracheostomy care trays which offer the ... control. Designed with the guidance of ... trays provide exactly what is required ...
... Each KIMBERLY-CLARK BALLARD Component ... T-Pieces, Elbows and Double ... configurations. Customer-oriented presentation to ... sterilized. Also available in ...
... permanent flexible tube extension on ... neck flange helps keep connections ... and stoma, enhancing patient mobility ... FlexTend™ tracheostomy tubes improve tube ...
... permanent flexible tube extension on ... neck flange helps keep connections ... and stoma, enhancing patient mobility ... FlexTend™ tracheostomy tubes improve tube ...
Medicine Products: